Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: Final analysis of GIDEON study in Italy;Scelte terapeutiche e trattamento con sorafenib nell'epatocarcinoma: Analisi finale dello studio GIDEON in Italia

Recenti Progressi in Medicina

Volumn 106, Issue 5, 2015, Pages 217-226

  D'Angelo, Salvatore ^a   Germano, Domenico ^b   Zolfino, Teresa ^c   Sansonno, Domenico ^d   Giannitrapani, Lydia ^e   Benedetti, Antonio ^f   Montesarchio, Vincenzo ^g   Attili, Adolfo ^h   Buonadonna, Angela ⁱ   Barni, Sandro ^j   Gasbarrini, Antonio ^k   Burlone, Michela E ^l   Cillo, Umberto ^m   Marenco, Simona ⁿ   Villa, Erica ^o   Giovanis, Petros ^p   Proserpio, Ilaria ^q   Saitta, Carlo ^r   Magini, Giulia ^s   Cengarle, Rita ^t   Fava, Giammarco ^f   Cuttone, Filiana ^u   Calvani, Nicola ^v   Angelico, Mario ^w   Di Costanzo, Francesco ^x   Noto, Alfonso ^y   Poggi, Guido ^z   Marignani, Massimo ^aa   Cascinu, Stefano ^f   Amoroso, Domenico ^ab   Palmieri, Vincenzo ^d   Massa, Elena ^ac   Crocè, Lory Saveria ^ad   Picardi, Antonio ^ae   Tumulo, Salvatore ^af   Erminero, Claudia ^ag   Lencioni, Riccardo ^ah   Lorusso, Vito ^ai   more..

^a S G MOSCATI HOSPITAL   (Italy)

^b AO Rummo   (Italy)

^c BROTZU HOSPITAL   (Italy)

^d POLICLINICO   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

^h POLICLINICO UMBERTO I   (Italy)

ⁱ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^j TREVIGLIO HOSPITAL   (Italy)

^k FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^l MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^m AOU di Padova   (Italy)

ⁿ UNIVERSITY OF GENOA   (Italy)

^o UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^p Azienda ULSS 9   (Italy)

^q OSPEDALE DI CIRCOLO   (Italy)

^r UNIVERSITY OF MESSINA   (Italy)

^s PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^t CARLO POMA HOSPITAL   (Italy)

^u AO Ospedali Riuniti Villa Sofia Cervello   (Italy)

^v Ospedale Perrino   (Italy)

^w TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^x CAREGGI UNIVERSITY HOSPITAL   (Italy)

^y AO di Cosenza PO Annunziata   (Italy)

^z IRCCS   (Italy)

^aa Sant Andrea University   (Italy)

^ab Ospedale Della Versilia   (Italy)

^ac DEPARTMENT OF RADIOLOGY   (Italy)

^ad UNIVERSITY OF TRIESTE   (Italy)

^ae Unit of Hematology Stem Cell Transplantation   (Italy)

^af Cardiology Unit   (Italy)

^ag Bayer SpA Italy   (Italy)

^ah CISANELLO HOSPITAL   (Italy)

^ai NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

more..

Author keywords

GIDEON study; Hepatocellular carcinoma; Sorafenib

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL DECISION MAKING; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; ITALY; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; FEMALE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; ITALY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROSPECTIVE STUDIES;

EID: 84930747671     PISSN: 00341193     EISSN: 20381840     Source Type: Journal    
DOI: 10.1701/1868.20406     Document Type: Article

References (26)

1. Globocan 2012: Estimated cancer incidence mortality and prevalence worldwide 2012. Available from: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
2. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013; 47 Suppl: S2-6.
3. http://www.registri-tumori.it/PDF/AIOM2014/I-numeri-del-cancro-2014.pdf
4. Okuda H. Hepatocellular carcinoma development in cirrhosis. Best Pract Res Clin Gastroenterol 2007; 21: 161-73.
5. Fattovich G1, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127 (5 suppl 1): S35-50.
6. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
7. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
8. Cabibbo G, Tremosini S, Galati G, et al. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. Expert Rev Anticancer Ther 2014; 14: 831-45.
9. Llovet JM, Ricci S, Mazzaferro V, et al.; SHARP Investigators Study Group: sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
10. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo controlled trial. Lancet Oncol 2009; 10: 25-34.
11. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
12. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
13. NCCN Guidelines Hepatobiliary cancer V.1.2015.
14. Kudo M, Izumi N, Kokudo N, et al.; HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-64.
15. Linee-guida AIOM epatocarcinoma edizione 2014 scaricabile dal sito: www.aiom.it
16. Italian Association for the Study of the Liver (AISF) Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis 2013; 45: 712-23.
17. Lencioni R, Kudo M, Ye SL, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014; 68: 609-17.
18. Lencioni R, Kudo M, Ye SL, et al. First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study. Int J Clin Pract 2012; 66: 675-83.
19. Marrero JA, Lencioni R, Ye SL, et al. Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in >3000 Sor-treated patients (pts): Clinical findings in pts with liver dysfunction. J Clin Oncol 2013; 31: (suppl) abstr 4126.
20. Lencioni R, Marrero J, Venook A, Ye SY, Kudo M. Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study. Int J Clin Pract 2010; 64: 1034-41.
21. Sorafenib riassunto delle caratteristiche del prodotto. Disponibile su: http://www.pharma.bayer.it
22. Bronowicki J, Lencioni R, Ye SL, et al. Final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib) in >3000 sorafenib-treated patients: prognostic value of baseline characteristics and staging systems. Eur J Cancer Supplements S617 abstract 2594.
23. Ganten TM, Stauber R, Schott E, et al. Final analysis of overall survival per subgroups of HCC patients in the prospective, non-interventional insight study treated with sorafenib. Ann Oncol 2014; 25 (suppl 4): iv246-iv247.
24. Iavarone M, Cabibbo G, Piscaglia F, et al.; SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54: 2055-63.
25. Di Costanzo GG, Tortora R, Iodice L, et al. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. Dig Liver Dis 2012; 44: 788-92.
26. Giannini EG, Farinati F, Ciccarese F, et al.; Italian Liver Cancer (ITA.LI.CA) group. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015; 61: 184-90.